Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other Non-Current Liabilities (2016 - 2020)

Syndax Pharmaceuticals (SNDX) has 6 years of Other Non-Current Liabilities data on record, last reported at $1000.0 in Q4 2020.

  • For Q4 2020, Other Non-Current Liabilities fell 80.0% year-over-year to $1000.0; the TTM value through Dec 2020 reached $1000.0, down 80.0%, while the annual FY2020 figure was $1000.0, 80.0% down from the prior year.
  • Other Non-Current Liabilities reached $1000.0 in Q4 2020 per SNDX's latest filing, down from $2000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $312000.0 in Q1 2018 and bottomed at $1000.0 in Q4 2020.
  • Average Other Non-Current Liabilities over 5 years is $143350.0, with a median of $148000.0 recorded in 2017.
  • Peak YoY movement for Other Non-Current Liabilities: soared 311.43% in 2016, then plummeted 97.76% in 2019.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $288000.0 in 2016, then rose by 7.64% to $310000.0 in 2017, then plummeted by 56.13% to $136000.0 in 2018, then plummeted by 96.32% to $5000.0 in 2019, then tumbled by 80.0% to $1000.0 in 2020.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $1000.0 in Q4 2020, $2000.0 in Q3 2020, and $3000.0 in Q2 2020.